Euralis Semences completed a €M 20 capital increase, subscribed to exclusively and equally by its historic minority shareholders, Unigrains and Sofiprotéol.
Subsidiary of the French cooperative group Euralis, Euralis Semences is positioned across the 3 pillars of the industry: research and development of new seed varieties, production and commercialization.
With consolidated sales of €M 210, Euralis Semences employs 1 390 people and has 12 research stations and more than 500 000 plots. Given its European dimension and the wealth of its genetic expertise, Euralis Semences holds a leading position in corn, sunflower, rapeseed, soybrean and sorghum seeds. The strengthening of its capital will contribute to the construction of a seed production plan in Russia, as well as to the acceleration of its international development via the proposed fusion with Caussade Semences. This consolidation would significantly strengthen the position of the Group in Europe by offering a wider range of products and varieties recognized by farmers and distributors.
“As a financial partner of Euralis Semences for more than 30 years, we are pleased to support the Group in this important new industrial project providing simplified access to the Russian market and presenting attractive growth opportunities,” says François-Xavier Masson, investment director with Unigrains.
“Seed expert for over 60 years, Euralis Semences stands apart for its capacity to innovate, its international development strategy and its marketing expertise focused on close proximity to distributors and farmers,” says Luc Ozanne, investment director with Sofiprotéol. “We are delighted to participate in this new phase through which Euralis Semences is giving itself the means to create a major European seeds player, adding new tools and new skills in high-growth markets.”
“By our side since the creation of Euralis Semences, we are delighted to count, once again, on the strategic and financial support of Unigrains and Sofiprotéol in the context of this major, new industrial project,” says Philippe Saux, CEO of Euralis. “This investment will support the commercial development of Euralis Semences, which is already well established in Russia and will enable us to achieve our objective to increase from 500,000 doses sold in the country today to 1 million doses in 2025.”
